QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

$15.73
+0.55 (+3.62%)
(As of 04:00 PM ET)
Today's Range
$15.25
$16.17
50-Day Range
$13.58
$17.36
52-Week Range
$9.90
$17.73
Volume
879,944 shs
Average Volume
541,996 shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

Deciphera Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
43.8% Upside
$23.00 Price Target
Short Interest
Bearish
11.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.50mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$58,734 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.16) to ($1.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

261st out of 938 stocks

Pharmaceutical Preparations Industry

116th out of 433 stocks

DCPH stock logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock Price History

DCPH Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Deciphera Pharmaceuticals, Inc. Q4 Loss beats estimates
Deciphera Pharmaceuticals LLC (DCPH)
Deciphera: Upside Potential For The Patient Investor
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
355
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$30.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+48.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-194,940,000.00
Net Margins
-119.33%
Pretax Margin
-119.07%

Debt

Sales & Book Value

Annual Sales
$163.36 million
Book Value
$4.38 per share

Miscellaneous

Free Float
77,221,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
0.39
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Steven L. Hoerter (Age 53)
    President, CEO & Director
    Comp: $1.24M
  • Mr. Thomas Patrick Kelly J.D.Mr. Thomas Patrick Kelly J.D. (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $778.85k
  • Mr. Daniel C. Martin (Age 49)
    Senior VP & Chief Commercial Officer
    Comp: $711.42k
  • Dr. Matthew L. Sherman M.D. (Age 68)
    Executive VP & Chief Medical Officer
    Comp: $865.62k
  • Dr. Kevin Brodbeck Ph.D.
    Senior VP & Chief Technical Officer
  • Dr. Dashyant Dhanak Ph.D. (Age 63)
    Executive VP & Chief Scientific Officer
  • Jennifer Larson
    Senior Vice President of Finance & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Senior VP & General Counsel
  • Ms. Lisa Amaya Price
    Senior VP & Chief Human Resources Officer
  • Ms. Jama Pitman (Age 44)
    Senior VP & Chief Development Officer

DCPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price target for 2024?

5 equities research analysts have issued 12 month target prices for Deciphera Pharmaceuticals' stock. Their DCPH share price targets range from $16.00 to $30.00. On average, they predict the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2024?

Deciphera Pharmaceuticals' stock was trading at $16.13 at the beginning of the year. Since then, DCPH shares have decreased by 0.8% and is now trading at $16.00.
View the best growth stocks for 2024 here
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its earnings results on Tuesday, February, 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. The firm had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 49.44% and a negative net margin of 119.33%. The firm's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.60) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.44%), Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.45%), Goldman Sachs Group Inc. (2.86%), Goldman Sachs Group Inc. (2.86%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners